Organon Inc. Receives "Stars of RESOLVE Award" for Support of Infertility Awareness

Strategic Insights -

Organon Inc., a leading international ethical pharmaceutical company, has been recognized by RESOLVE of New Jersey for its dedication to helping couples in the state and worldwide realize their dream of having children through assisted reproductive technology (ART). The company's support of advocacy efforts and commitment to providing education and treatment to those suffering from infertility have earned them the "Stars of RESOLVE Award". Infertility affects approximately 6.1 million couples in the United States, with around 353,000 individuals residing in New Jersey.

Key Takeaways:

  • Organon Inc. received the "Stars of RESOLVE Award" from RESOLVE's New Jersey chapter for their assistance and support of advocacy efforts.
  • The award recognizes Organon's commitment to helping couples in New Jersey and worldwide realize their dream of having children through ART.
  • Infertility affects approximately 6.1 million couples in the United States, with around 353,000 individuals residing in New Jersey.
  • RESOLVE of New Jersey provides help to thousands of people experiencing the crisis of infertility through advocacy and public education.
  • Organon Inc. is a leading international ethical pharmaceutical company that specializes in reproductive health products, including FOLLISTIM (R), HUMEGON (TM), and PREGNYL (R).
  • The company has an unprecedented commitment to healthcare, conducting research in various areas, including psychiatry, contraception, fertility, anesthesiology, thrombosis, immunology, osteoporosis prevention, and treatment of post-menopausal symptoms.
  • Akzo Nobel, Organon's parent company, employs 86,000 people worldwide and has consolidated sales of $13.8 billion in 1998.
  • In North America, Akzo Nobel employs approximately 10,000 people and has annual sales of around $3 billion.

Statistics:

  • Infertility affects approximately 6.1 million couples in the United States, or about 10 percent of the reproductive age population.
  • Approximately 353,000 individuals residing in New Jersey are affected by infertility.
  • RESOLVE of New Jersey provides help to thousands of people experiencing the crisis of infertility.
  • Akzo Nobel, Organon's parent company, has consolidated sales of $13.8 billion in 1998.
  • In North America, Akzo Nobel employs approximately 10,000 people and has annual sales of around $3 billion.

Sources:

  • RESOLVE of New Jersey
  • PRNewswire, July 8 (no year provided)
  • Organon Inc. press release
  • Akzo Nobel N.V. press release (no date provided)